Peripheral refraction in Japanese schoolchildren with low to moderate myopia.

PURPOSE: To report the profile of peripheral refraction in Japanese children with mild to moderate myopia and compare it with reported data from other countries. STUDY DESIGN: Cross-sectional study. METHODS: Subjects were 76 Japanese children with myopia (mean± SD [range] spherical equivalent, -3.04±0.98 [-0.50 to -4.50] D; mean age, 10.0±1.5 [6-12] years). We performed cycloplegic refraction using an open-field autorefractor FR-5000 (Grand Seiko) while the subject looked at external fixation targets located at 0, ±15, ±30 degrees from the center along the horizontal meridian. Only the right eye data were analyzed after converting the readings to the power vector of M (spherical equivalent), J180, and J45. RESULTS: The profile showed a clear hyperopic shift of M from the fovea to the peripheral retina, although a wide inter-subject variation existed. At the gaze positions of ±30 degrees, the mean relative M were +1.16±0.89 D and +1.64±1.02 D (nasal and temporal retina, respectively). Those for J180 were -0.94±0.30 D and -0.70±0.30 D (nasal and temporal retina, respectively). The mean J45 remained small (≦ 0.17 D) within this range of eccentricity. There was no correlation between the relative M at the gaze position of -30 degrees and on-axis refraction, axial length, or children's age (p > 0.05). CONCLUSIONS: The profile of peripheral refraction was similar to that reported in children with moderate to high myopia in other East Asian countries. In this cohort, we did not find evidence supporting a hypothesis that greater myopia and longer axial length are associated with a greater peripheral hyperopic shift of the refraction.

Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.

PURPOSE: Atropine eye drops prevent the progression of myopia, but their use has not been tested in the Japanese schoolchildren population. Here, we evaluate the efficacy and safety of 0.01% atropine eye drops for myopia control in Japanese children. STUDY DESIGN: Multicenter (7 university hospitals), randomized, double-masked, placebo-controlled trial. METHODS: Participants were 171 Japanese schoolchildren aged 6 to 12 years, with progressive myopia, spherical equivalence (SE) of -1.00 to -6.00 diopters (D), and astigmatism of ≤1.5 D. They were randomized to receive either 0.01% atropine (n=85) or placebo (n=86) eye drops once nightly OU for 24 months. Primary and secondary efficacy endpoints were changes in SE and axial length (AL), respectively, from baseline to month 24. RESULTS: Data from 168 subjects were analyzed. At month 24, compliance was similar in both groups (atropine: 83.3%; placebo: 85.7%). The least squares mean change in SE and AL from baseline were, respectively, -1.26 D (95% confidence interval [CI]: -1.35, -1.17) and 0.63 mm (0.59, 0.67) for atropine and -1.48 D (- 1.57, -1.39) and 0.77 mm (0.73, 0.81) for placebo. Inter-group differences were 0.22 D (95% CI: 0.09, 0.35; P < 0.001) for SE and - 0.14 mm (-0.20, -0.08; P < 0.001) for AL. Three patients experienced mild allergic conjunctivitis side effects, with no inter-group difference in incidence (atropine: 2.4%; 2/84 patients; placebo: 1.4%; 1/84 patients). CONCLUSION: With good compliance, 0.01% atropine is effective and safe for preventing the progression of childhood myopia.

Adverse reactions to 1% cyclopentolate eye drops in children: an analysis using logistic regression models.

PURPOSE: To determine the frequency, symptoms and risk factors for adverse reactions to two-times instillation of 1% cyclopentolate in children. STUDY DESIGN: Prospective, observational study. METHODS: The subjects were 646 patients who underwent cycloplegic refraction with cyclopentolate (mean age; 7.0 ± 3.5 years, age range; 0-15 years). Five minutes after instillation of 0.4% oxybuprocaine hydrochloride, a 1% cyclopentolate eye drop was instilled twice, with an interval of 10 min. Fifty minutes later, two certified orthoptists evaluated adverse reactions using a questionnaire and interviewed the patients' guardians. The relationship between the adverse reaction rates and age, gender, additional instillation, complications of the central nervous system (CNS), time of day and season were analysed using binominal and polytomous logistic regression models. RESULTS: The overall frequency of adverse reactions was 18.3% (118/646 patients). The main symptoms included conjunctival injection (10.5%, 68/646), drowsiness (6.8%, 44/646) and facial flush (2.2%, 14/646). The odds ratio (OR) of conjunctival injection increased with patient's age (p < 0.05), in boys (p < 0.01) and in winter (p < 0.001). In contrast, the OR of drowsiness decreased with age (p < 0.001). Facial flush was observed mostly in children younger than 4 years. CNS complications were not a significant risk factor for any of the symptoms. CONCLUSIONS: Adverse reactions to 1% cyclopentolate eye drops were more frequent than previously expected, but all were mild and transient. The probability of each symptom was associated with a clear age-specific trend.

Repeatability of visual acuity testing using a psychometric function.

PURPOSE: To evaluate the repeatability of a new method of measurement of visual acuity by use of a psychometric function. METHODS: The visual acuity of 15 healthy adults was measured by use of a psychometric function (PFVA) and by use of a conventional method using a decimal visual acuity chart (DeVA). We performed two tests. To evaluate intra-rater reliability, a tester measured the visual acuity three times for each subject, and the intraclass correlation coefficients, ICC (1,1), were calculated for PFVA and DeVA. Next, to evaluate inter-rater reliability, three testers measured the visual acuity for one subject, and the ICC (2,1) were calculated for PFVA and DeVA. The PFVA and DeVA of five subjects with ocular diseases were also measured. RESULTS: In the evaluation of intra-rater reliability, the ICC (1,1) of the DeVA was 0.83 and the ICC (1,1) of the PFVA was 0.95. In the evaluation of inter-rater reliability, the ICC (2,1) of the DeVA was 0.88 and the ICC (2,1) of the PFVA was 0.93. In both tests the standard deviations of the PFVA were significantly lower than those of the DeVA. For four of the five subjects with ocular diseases, the PFVA was significantly improved by treatment. CONCLUSION: The repeatability of our method is better than that of the conventional method using a decimal visual acuity chart.